BeOne Medicines (ONC) Debt to Equity: 2015-2025
Historic Debt to Equity for BeOne Medicines (ONC) over the last 10 years, with Sep 2025 value amounting to $0.40.
- BeOne Medicines' Debt to Equity rose 30.28% to $0.40 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.40, marking a year-over-year increase of 30.28%. This contributed to the annual value of $0.31 for FY2024, which is 21.97% up from last year.
- As of Q3 2025, BeOne Medicines' Debt to Equity stood at $0.40, which was up 57.47% from $0.25 recorded in Q2 2025.
- BeOne Medicines' Debt to Equity's 5-year high stood at $0.40 during Q3 2025, with a 5-year trough of $0.10 in Q4 2021.
- In the last 3 years, BeOne Medicines' Debt to Equity had a median value of $0.26 in 2025 and averaged $0.26.
- Per our database at Business Quant, BeOne Medicines' Debt to Equity soared by 392.27% in 2021 and then slumped by 37.62% in 2022.
- BeOne Medicines' Debt to Equity (Quarterly) stood at $0.10 in 2021, then increased by 12.65% to $0.12 in 2022, then spiked by 116.54% to $0.25 in 2023, then climbed by 21.97% to $0.31 in 2024, then spiked by 30.28% to $0.40 in 2025.
- Its Debt to Equity stands at $0.40 for Q3 2025, versus $0.25 for Q2 2025 and $0.26 for Q1 2025.